Core Insights - Veeva Systems reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.95 per share, and up from $1.75 per share a year ago [1][2] - The company achieved revenues of $811.24 million for the quarter, surpassing the Zacks Consensus Estimate by 2.44% and increasing from $699.21 million year-over-year [3] - Veeva has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2][3] Earnings Performance - The earnings surprise for the recent quarter was +4.62%, following a previous surprise of +4.74% [2] - The current consensus EPS estimate for the upcoming quarter is $1.87, with expected revenues of $798.22 million, while the estimate for the current fiscal year is $7.78 on $3.14 billion in revenues [8] Stock Performance - Veeva shares have increased approximately 29.8% since the beginning of the year, compared to a 12.9% gain for the S&P 500 [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Industry Outlook - The Medical Info Systems industry, to which Veeva belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]

Financial Performance - Biotricity Inc. reported a quarterly loss of $0.03 per share, better than the Zacks Consensus Estimate of a loss of $0.08, and an improvement from a loss of $0.07 per share a year ago, representing an earnings surprise of +62.50% [1] - The company posted revenues of $3.89 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.36%, but showing an increase from $3.27 million in the same quarter last year [2] Stock Performance - Biotricity shares have increased approximately 82.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.6% [3] - The current Zacks Rank for Biotricity is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $4.1 million, and for the current fiscal year, it is -$0.32 on revenues of $15.8 million [7] - The estimate revisions trend for Biotricity was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - Biotricity operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 31% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Nyxoah SA reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.61, and compared to a loss of $0.55 per share a year ago, indicating a significant earnings surprise of -21.31% [1] - The company generated revenues of $2.31 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 18.02%, and showing an increase from $1.39 million in the same quarter last year [2] - Nyxoah shares have declined approximately 26.4% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Nyxoah has only surpassed consensus EPS estimates once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.58 on revenues of $3.59 million, and for the current fiscal year, it is -$2.52 on revenues of $8.34 million [7] Market Outlook - The estimate revisions trend for Nyxoah was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), suggesting expected underperformance in the near future [6] - The outlook for the Medical Info Systems industry, where Nyxoah operates, is currently in the top 30% of over 250 Zacks industries, indicating a favorable environment that could impact stock performance positively [8]

Company Performance - Veeva Systems (VEEV) closed at $291.70, down 1.77% from the previous trading session, underperforming compared to the S&P 500's loss of 1.66% [1] - The stock has increased by 3.33% over the past month, which is lower than the Medical sector's gain of 6.4% and the S&P 500's gain of 4.64% [1] Upcoming Earnings - Veeva Systems is set to release its earnings report on November 20, 2025, with projected earnings of $1.95 per share, reflecting a year-over-year growth of 11.43% [2] - The consensus estimate for quarterly revenue is $791.88 million, indicating a 13.25% increase from the same period last year [2] Full Year Estimates - For the full year, earnings are projected at $7.78 per share and revenue at $3.14 billion, showing increases of 17.88% and 14.26% respectively from the previous year [3] Analyst Estimates and Stock Performance - Changes in analyst estimates for Veeva Systems are closely monitored, as positive revisions indicate optimism about the business outlook [3] - The Zacks Rank system, which incorporates estimate changes, currently ranks Veeva Systems at 2 (Buy) [5] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 38.18, which is higher than the industry average of 34.81 [5] - The company has a PEG ratio of 1.63, compared to the Medical Info Systems industry's average PEG ratio of 3.09 [6] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 72, placing it in the top 30% of over 250 industries [6][7] - The Zacks Industry Rank measures the strength of industry groups based on the average Zacks Rank of individual stocks, with the top 50% rated industries outperforming the bottom half by a factor of 2 to 1 [7]

Core Insights - KORU Medical Systems, Inc. reported a quarterly loss of $0.02 per share, better than the Zacks Consensus Estimate of a loss of $0.03, marking an earnings surprise of +33.33% [1] - The company achieved revenues of $10.4 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.07% and showing a year-over-year increase from $8.18 million [2] - The stock has underperformed the market, losing approximately 3.1% year-to-date compared to the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $10.52 million, and for the current fiscal year, it is -$0.08 on revenues of $40.1 million [7] - The estimate revisions trend for KORU Medical Systems was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical Info Systems industry, to which KORU Medical Systems belongs, is currently ranked in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Phreesia, is expected to report a quarterly loss of $0.01 per share, reflecting a year-over-year change of +96%, with revenues projected at $120.19 million, up 12.5% from the previous year [9][10]

分组1 - Pulmonx Corporation reported a quarterly loss of $0.34 per share, which was better than the Zacks Consensus Estimate of a loss of $0.40, representing an earnings surprise of +15.00% [1] - The company achieved revenues of $21.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.10% and showing an increase from $20.39 million year-over-year [2] - Over the last four quarters, Pulmonx has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed significantly, losing about 69.2% since the beginning of the year, while the S&P 500 has gained 16.4% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $23.83 million, and for the current fiscal year, it is -$1.51 on revenues of $90.89 million [7] - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 20% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - Outset Medical, Inc. reported a quarterly loss of $0.69 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.64, marking an earnings surprise of -7.81% [1] - The company's revenues for the quarter ended September 2025 were $29.43 million, missing the Zacks Consensus Estimate by 3.19%, but showing an increase from $28.67 million year-over-year [2] - Outset Medical shares have declined approximately 27.5% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - Over the last four quarters, Outset Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $32.4 million, and for the current fiscal year, it is -$3.96 on revenues of $124 million [7] Market Outlook - The company's stock performance in the near future is expected to align with the market, as indicated by a Zacks Rank 3 (Hold) [6] - The outlook for the Medical Info Systems industry, where Outset Medical operates, is relatively strong, ranking in the top 27% of over 250 Zacks industries [8]

Core Insights - Health Catalyst (HCAT) reported quarterly earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, but down from $0.07 per share a year ago [1][2] - The company achieved a revenue of $76.32 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.66%, and slightly down from $76.35 million year-over-year [3] Earnings Performance - The earnings surprise for the quarter was +20.00%, following a previous surprise of +33.33% when earnings were $0.04 per share against an expectation of $0.03 [2] - Over the last four quarters, Health Catalyst has exceeded consensus EPS estimates two times and revenue estimates three times [2][3] Stock Performance - Health Catalyst shares have declined approximately 60% since the beginning of the year, contrasting with the S&P 500's gain of 14.4% [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.10 on revenues of $74.59 million, and for the current fiscal year, it is $0.19 on revenues of $309.8 million [8] - The Medical Info Systems industry, to which Health Catalyst belongs, is ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [9]

分组1 - Claritev Corporation reported a quarterly loss of $4.07 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.12, and compared to a loss of $1.85 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $245.96 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.87% and showing an increase from $230.49 million in the same quarter last year [2] - Claritev Corporation's shares have increased approximately 319.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.3% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is -$3.07 on revenues of $236.34 million, and for the current fiscal year, it is -$14.36 on revenues of $943.77 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Insights - Evolent Health reported quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.10 per share, but showing an improvement from $0.04 per share a year ago [1] - The company experienced an earnings surprise of -50.00% and has not surpassed consensus EPS estimates in the last four quarters [2] - Evolent Health's revenues for the quarter were $479.53 million, exceeding the Zacks Consensus Estimate by 2.81%, but down from $621.4 million year-over-year [3] Financial Performance - The earnings report indicates a significant decline in stock performance, with shares down approximately 43.6% year-to-date compared to a 15.6% gain in the S&P 500 [4] - The current consensus EPS estimate for the upcoming quarter is $0.11 on revenues of $471.15 million, and for the current fiscal year, it is $0.18 on revenues of $1.87 billion [8] Industry Context - Evolent Health operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The company has a Zacks Rank of 4 (Sell), indicating expectations of underperformance in the near future based on unfavorable estimate revisions [7]